Center for Neuroendocrine Tumors
The UCSF Center for Neuroendocrine Tumors provides comprehensive care for patients with all types of neuroendocrine tumors (NETs). Arising from cells that have traits of both nerve cells and endocrine cells, these rare tumors may produce hormones and can develop in many parts of the body, including the head and neck, lungs, pancreas and digestive tract.
We're equipped to handle any NET, no matter where it appears in the body or how it behaves. Our team includes surgeons, medical oncologists, radiation oncologists, radiologists, cardiologists, endocrinologists, symptom management experts, genetic counselors, nutritionists, psychologists, social workers and other specialists. We work together to provide patients with a precise diagnosis and treatment plan tailored to their particular case and needs.
All of our patients can expect to receive the latest and most effective therapies available for their condition. For a patient with a pancreatic NET, for example, the best treatment might involve minimally invasive surgery to remove the tumor. A patient with a gastrointestinal tumor might benefit from peptide receptor radionuclide therapy (PRRT), a new radiation technique that targets cancer cells. And we might use advanced screening tools, such as the UCSF500 Cancer Gene Panel test, to identify the precise biology behind another patient's tumor.
Our goal is to deliver world-class care from a holistic perspective. We make sure that our patients and their families have the support they need to face the physical, emotional and financial challenges that can arise after a cancer diagnosis. UCSF offers a wide range of cancer support services, including a bimonthly education and support group for patients with NETs and their loved ones.
MD, PhDRadiation oncologist
MD, FACSGastrointestinal cancer surgeon
MD, MPHGastrointestinal oncologist
NP, MSNNurse practitioner
MD, PhDGastrointestinal cancer surgeon
MD, MPHGastrointestinal oncologist
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...
A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...
Adverse events, serious adverse events, and dose limiting toxicities
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prost...
The composite response rate is determined by a combination of a decline from baseline in serum PSA of >= 50%, confirmed by repeat measurement ≥ 4 weeks later (PSA50) AND/OR a complete response (CR) or partial response (PR) as dete...
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by retrospective independent central review. Will be compared between treatment arms using the stratified log rank test at one-sided level 0...
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine T...
The point estimate and 95% confidence interval of overall response rate will be obtained for each of the three liver-directed therapy groups (cryoablation, transarterial embolization(TAE) , radioembolization (RE)) separately. The ...
Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...
The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Patients who discontinue ap...
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Pati...
U.S. News rankings
Among the top hospitals in the nation
Best in Northern California for cancer care (tie)
Accreditations & memberships
National Cancer Institute
The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
Commission on Cancer
UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
National Comprehensive Cancer Network
UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes